These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 29761371

  • 1. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
    Nolte F, Nückel H, Schmidt B, Geer T, Rubanov O, Hebart H, Jarisch A, Albrecht S, Johr C, Schumann C, Hofmann WK.
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1531-1538. PubMed ID: 29761371
    [Abstract] [Full Text] [Related]

  • 2. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
    Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW, Kim YS, Lee HS, Kwon KY, Kim SH, Park KT, Chung JS, Lee WS, Lee SM, Hyun MS, Kim H, Ryoo HM, Bae SH, Joo YD.
    Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
    [Abstract] [Full Text] [Related]

  • 4. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
    Antmen B, Karakaş Z, Yeşilipek MA, Küpesiz OA, Şaşmaz İ, Uygun V, Kurtoğlu E, Oktay G, Aydogan G, Akın M, Salcioglu Z, Vergin C, Kazancı EG, Ünal S, Çalışkan Ü, Aral YZ, Türkkan E, Meral Güneş A, Tunç B, Gümrük F, Ayhan AC, Söker M, Koç A, Oymak Y, Ertem M, Timur Ç, Yıldırmak Y, İrken G, Apak H, Biner B, Eren TG, Işık Balcı Y, Koçak Ü, Karasu G, Akkaynak D, Patıroğlu T.
    Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, Sherief L, Christou S, Cosmi C, Della Pasqua O, Del Vecchio GC, Filosa A, Cuccia L, Hassab H, Kreka M, Origa R, Putti MC, Spino M, Telfer P, Tempesta B, Vitrano A, Tsang YC, Zaka A, Tricta F, Bonifazi D, Ceci A.
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [Abstract] [Full Text] [Related]

  • 6. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [Abstract] [Full Text] [Related]

  • 8. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
    Di Veroli A, Campagna A, De Muro M, Maurillo L, Trawinska MM, LeonettiCrescenzi S, Petriccione L, Romano A, D'Addosio A, Cenfra A, Montanaro M, Felici S, Andriani A, Carmosino I, Niscola P, Montefusco E, Breccia M, Latagliata R.
    Leuk Res; 2019 Jan; 76():65-69. PubMed ID: 30578958
    [Abstract] [Full Text] [Related]

  • 9. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
    Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A, EPIC Study Investigators.
    Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979
    [Abstract] [Full Text] [Related]

  • 10. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A.
    Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
    [Abstract] [Full Text] [Related]

  • 11. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
    Escudero-Vilaplana V, Garcia-Gonzalez X, Osorio-Prendes S, Romero-Jimenez RM, Sanjurjo-Saez M.
    J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
    [Abstract] [Full Text] [Related]

  • 12. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
    Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G, TELESTO Study Investigators.
    Ann Intern Med; 2020 Apr 21; 172(8):513-522. PubMed ID: 32203980
    [Abstract] [Full Text] [Related]

  • 13. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.
    Cochrane Database Syst Rev; 2010 Aug 04; (8):CD007477. PubMed ID: 20687088
    [Abstract] [Full Text] [Related]

  • 14. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
    OKABE H, SUZUKI T, OMORI T, MORI M, UEHARA E, HATANO K, UEDA M, MATSUYAMA T, TOSHIMA M, QZAKI K, NAGAI T, MUROI K, OZAWA K.
    Rinsho Ketsueki; 2009 Nov 04; 50(11):1626-9. PubMed ID: 20009438
    [Abstract] [Full Text] [Related]

  • 15. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.
    Aydinok Y, Unal S, Oymak Y, Vergin C, Türker ZD, Yildiz D, Yesilipek A.
    Eur J Haematol; 2012 May 04; 88(5):431-8. PubMed ID: 22335829
    [Abstract] [Full Text] [Related]

  • 16. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 04; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 17. Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
    Del Corso L, Biale L, Parodi EL, Russo R, Filiberti R, Arboscello E.
    Int J Clin Oncol; 2017 Apr 04; 22(2):380-386. PubMed ID: 27771776
    [Abstract] [Full Text] [Related]

  • 18. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
    Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M.
    Curr Med Res Opin; 2018 Nov 04; 34(11):1959-1966. PubMed ID: 29701080
    [Abstract] [Full Text] [Related]

  • 19. CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
    Bruch HR, Dencausse Y, Heßling J, Michl G, Schlag R, Skorupa A, Schneider-Schranz C, Wolf S, Schulte C, Tesch H.
    Oncol Res Treat; 2016 Nov 04; 39(7-8):424-31. PubMed ID: 27486873
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH, Shu KH, Yang Y.
    Hematology; 2015 Jun 04; 20(5):304-10. PubMed ID: 25200910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.